Catalent Expands Technology Offerings in Biologics
Catalent has acquired the remaining stake in Redwood Bioscience Inc., and the SMARTag™ Antibody Drug Conjugate (ADC) technology platform. In Catalent’s first acquisition since its IPO in July, the company continues to execute its strategy to build a differentiated technology offering and strengthen its position in the fast growing biologics market.
Every molecule has a challenge. We have a solution.
Discover innovative solutions to improve the value of your treatments at every stage.
Find the best oral drug delivery technology options for your challenging molecule.
Learn more about our tailored solutions for Consumer Health, Animal Health & Biologics.